Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

47.66 +2.04 (+4.47%)
Streaming Delayed Price Updated: 11:58 AM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Alnylam Jumps As A New Approval Sets Up Its Next Battle With Pfizer, BridgeBio
Alnylam added a gene silencer to the cardiomyopathy space this week, and will now rival Pfizer and BridgeBio. 
Via Investor's Business Daily
BridgeBio Announces CFO Succession
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Prediction: BridgeBio Pharma Will Beat the Market. Here's Why
Via The Motley Fool
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Earnings Scheduled For February 20, 2025
 
Via Benzinga
BridgeBio Prices Offering of $500 Million Convertible Senior Notes due 2031 to Refinance Senior Secured Debt
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Initiates Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes to Refinance Senior Secured Debt
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Commercial Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Business Update on February 20, 2025
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BEYONTTRA™ (acoramidis), the First Near Complete TTR Stabilizer (≥90%), Approved by the European Commission to Treat ATTR-CM
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Top 4 Health Care Stocks You May Want To Dump In Q1
 
Via Benzinga
Stock Market Rises On Tame Inflation, Bank Earnings: Weekly Review
Many stocks flashed buy signals as the major indexes rose to or above key levels. 
Via Investor's Business Daily
Topics Economy
BridgeBio Pharma Stock Earns 87 RS Rating
BridgeBio Pharma stock saw a positive improvement to its Relative Strength (RS) Rating on Tuesday, with an increase from 64 to 87. 
Via Investor's Business Daily
BridgeBio, ARS Pharma, Harmony Bio Shine At JPM. But SpringWorks, Beam Take Their Lumps.
Some companies saw their shares skyrocket on preliminary reports, but others took hits. 
Via Investor's Business Daily
BridgeBio Announces Commercial Progress, Program Updates, and 2025 Milestones
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
From BridgeBio Pharma, Inc.
Via GlobeNewswire
Acoramidis Receives Positive CHMP Opinion for Treatment of Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
From BridgeBio Pharma, Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Gold Down Over 3%; Rigetti Computing Shares Spike Higher
 
Via Benzinga
Crude Oil Down 3%; Chicago Fed National Activity Index Falls In October
 
Via Benzinga
Topics Economy
BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday
 
Via Benzinga
BridgeBio Catapults After Snagging Approval For Pfizer-Rivaling Heart Drug
BridgeBio will sell its drug at a slightly lower wholesale acquisition cost compared to Pfizer's blockbuster, Vyndaqel. 
Via Investor's Business Daily
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, Poised To Challenge Pfizer In Lucrative Yet Competitive Market
FDA approves BridgeBio's Attruby for ATTR-CM. Phase 3 results highlight its effectiveness in reducing cardiovascular risks and improving life quality. 
Via Benzinga
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), approved by FDA to Reduce Cardiovascular Death and Cardiovascular-related Hospitalization in ATTR-CM Patients
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma's Acoramidis Shows Competitive Edge Against Pfizer's Tafamidisa In Lucrative But Competitive ATTR-CM Market
BridgeBio's acoramidis shows significant reductions in mortality and hospitalizations in ATTR-CM patients, with no new safety concerns in long-term studies. 
Via Benzinga
Open-Label Extension Data Confirms Sustained Benefit of Acoramidis on Cardiovascular Outcomes, Including Statistically Significant Reduction in ACM Within 36 Months
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Announces Publication in the New England Journal of Medicine of Phase 2 PROPEL 2 Study of Infigratinib for Children Living with Achondroplasia
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Pharma Reports Third Quarter 2024 Financial Results and Business Update
From BridgeBio Pharma, Inc.
Via GlobeNewswire
BridgeBio Announces Publication of Case Study Exploring Portfolio Theory’s Impact on Biomedical Innovation in The Journal of Portfolio Management
From BridgeBio Pharma, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.